source
- Beam Therapeutics reports year-long reduction in sickle cell crises in phase 1/2 risto-cel studyBeam Therapeutics disclosed data from its phase 1/2 trial of risto-cel, a base-edited autologous cell therapy targeting the BCL11A gene in sickle cell disease. The trial enrolled 31 adults and ado…
- FDA issues early alert as Arrow International recalls guidewires with spring wire guide componentsThe FDA's Center for Devices and Radiological Health has issued an early alert about a potential high‑risk issue with certain Arrow International guidewire products that contain spring wire guide c…